SecBot SecBot

KROS

Keros Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· CIK 0001664710 Biotech & Drug Discovery
$10.03 −0.27 (−2.62%)
Nov 16 4:00 PM ET · prev $10.30
Market cap
$197.8M
Micro cap
Median target
🔒 Subscribers only
1 year
−42.3%
from $17.37 · Nov 17
30 days
−9.3%
from $11.06
52-week range
$9.17–21.84
−54% from high · low Nov 9
Avg volume 20D
188.6K
Nov 12 spike 630.1K
Short interest
1.09M
≈5.5% of shares · −4.5%
Days to cover
7.1
at average volume
Insider net
−$447.2K
1 buyer · 9 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
23
analyzed by SecBot
SecBot read MIXED 12 reports · 90 days
Balance 0 bearish · 1 bullish · 11 neutral oldest → newest, height = score
Avg score ·High conf. 10/12

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

  • Feb 18 to Feb 19 ▼ 2 days of insider sells: $331.8K by 4 insiders, avg $16.29
  • Mar 9 ▲ 1 insider buy $22.4K at $11.21
  • Apr 15 ▲ 1 insider buy $11.7K at $11.70
  • May 15 ▲ 1 insider buy $10.6K at $10.58
  • Jun 4 to Jun 11 ▼ 2 days of insider sells: $90.0K by 4 insiders, avg $10.68
  • Jun 15 ▲ 1 insider buy $10.2K at $10.19
  • Jul 15 ▲ 1 insider buy $10.6K at $10.61
  • Aug 17 ▲ 1 insider buy $10.3K at $10.27
  • Aug 18 ▼ 4 insiders sell $101.1K at $10.29
  • Sep 8 Contract: Keros Therapeutics Announces $5 Million Share Repurchase A…
  • Sep 28 FDA: Keros Therapeutics Announces the First Patient Dosing in t…
  • Sep 29 ▲ Keros Therapeutics announced a $20 million development milestone pay…
  • Nov 16 New catalyst: subscribers see the details Unlock

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $75.8K at an average $10.82. 9 insiders sold $522.9K. Price is 7% below their cost.

  • InstitutionsMIXED

    Q3 2026: 18 added (0 new), 15 trimmed or exited.

  • Short sellersSTEADY

    Short interest −4.5% to 1.09M shares. 7.1 days to cover, ≈5.5% of shares.

  • TrendDOWNTREND

    9% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.ADD3,501,452$39.9M
Qube Research & Technologies LtdTRIM435,439$5.0M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPTRIM172,733$2.0M
MORGAN STANLEYADD135,412$1.5M
MARSHALL WACE, LLPDOUBLED115,770$1.3M
Quantinno Capital Management LPDOUBLED93,242$1.1M
BNP PARIBAS FINANCIAL MARKETSADD79,498$906.3K
Connor, Clark & Lunn Investment Management Ltd.TRIM72,139$822.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Aug 2026

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Aug 4, 2026Wells Fargo
MAINTAIN
MAINTAINOverweight
Aug 4, 2026Leerink Partners
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$75.8K
bought · 1 insider
$522.9K
sold · 9 insiders
−7.3%
vs their $10.82 cost
DateInsiderTypeValue
Aug 18, 2026
Newton Charles W.
Director
Aug 18, 2026
SELL$5.7K
Aug 18, 2026
Tanini Annita
Corp. Controller & VP, Finance
Aug 18, 2026
SELL$12.6K
Aug 18, 2026
Cho Esther
Chief Legal Officer
Aug 18, 2026
SELL$46.2K
Aug 18, 2026
Lerner Lorena Raquel
Chief Scientific Officer
Aug 18, 2026
SELL$36.7K
Aug 17, 2026
BIENAIME JEAN JACQUES
Director
Aug 17, 2026
BUY$10.3K
Jul 15, 2026
BIENAIME JEAN JACQUES
Director
Jul 15, 2026
BUY$10.6K
Jul 1, 2026
Prener Anne
Director
Jul 1, 2026
AWARD14,870 sh
Jul 1, 2026
Prener Anne
Director
Jul 1, 2026
AWARD13,786 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
1,086,309
shares short
-4.5%
vs prior settlement
7.1
days to cover
≈5.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Recent

SecBot reports

23 filings · 4 press releases · 2 bullish · 2 bearish · 2 mixed · 17 neutral
All KROS filing & press-release reports (27)